An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect and evaluate information on the use of Depakote
Extended Release (ER) and Depacon Intravenous (IV) in patients with cluster headaches.
Patients who are currently in a cluster cycle will be treated with 2 consecutive days of IV
Depacon followed by oral Depakote ER. Patients will receive a total of 1,000mg of Depacon and
1,000mg of Depakote ER each day. Patients may have a 3rd day of IV Depacon followed by oral
Depakote ER if the primary investigator believes it to be beneficial. The patient is then
sent home on oral Depakote ER. The dose of Depakote ER can range from 500mg to 2,000mg this
dose is to be determined by the primary investigator. The patient will continue the oral
Depakote ER until the end of their cluster cycle or for a maximum of 6 weeks, which ever
comes first.